This is the authors' abstract. We don't add key points for this paper.
Mycobacterium avium complex pulmonary disease (MAC-PD) is a refractory infectious disease, with a low success rate of the antimicrobial therapy. T cells and macrophages play a critical role in regulating the mechanism of immunity against mycobacterial infections. Although T cell dysfunction may be associated with treatment failure in MAC-PD, supporting evidence is scarce. This study aimed to elucidate the immunological characteristics of patients with refractory MAC-PD, focusing on immunosuppression and T cell exhaustion. Patients with MAC-PD who received standard antimicrobial therapy for at least 12 months were enrolled and classified into treatment success or failure groups. Flow cytometry was used to investigate CD4 + and CD8 + T cell characteristics in peripheral blood mononuclear cells. This study involved 41 patients, including 21 and 20 in the treatment success and failure groups, respectively. Patients with MAC-PD had higher expression of co-inhibitory molecules, including PD-1 and TIM-3, as well as CD160, LAG-3, and 2B4, on CD4 + and CD8 + T cells than healthy controls. However, no differences in expression were observed between the treatment success and failure groups for most activation, co-stimulatory, and co-inhibitory molecules and transcription factors. Furthermore, no difference in effector cytokine production (IL-2, TNF, and IFN-γ) in CD4 + and CD8 + T cells was observed between the groups. However, patients with MAC-PD with low IL-2-producing CD8⁺ T cells had a significantly longer disease duration than those with moderate and high IL-2-producing status (138.3 vs. 42.7 months). CD8 + T cells from patients with MAC-PD with low IL-2 production and prolonged disease duration tended to express higher 2B4 and lower CD28 levels. The effector functions of CD4 + and CD8 + T cells are not lost during treatment failure. However, low CD8 + T cell IL-2 production was significantly associated with longer disease duration. High 2B4 and low CD28 expression on CD8 + T cells may represent potential markers of T cell dysfunction. Such patients may serve as suitable targets for future host-directed therapies. This study was registered with the University Hospital Medical Information Network of Japan (registration number: UMIN000043426, registration date: March 1, 2021).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Matsuura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: